Abstract: Provided are combination therapies comprising inavolisib (a.k.a. GDC-0077) and other HER2-targeted therapies (e.g., pertuzumab and trastuzumab) for the treatment of HER2-positive cancers; and methods of treating HER2 positive (HER2+) cancers in a patient (preferably a patient with a PIK3CA mutant breast cancer) comprising administering a therapeutically effective amount of inavolisib and a HER2-targeted therapy (e.g., trastuzumab, pertuzumab, or a combination of trastuzumab and pertuzumab).

Abstract: Methods relating to selective inhibitors of the casein kinase 1 isoforms that are useful for the treatment of inflammatory diseases are presented.

Abstract: Disclosed herein is mobile middleware, a context monitoring method, a context-aware system, and a context-aware service provision method, which support energy-efficient context monitoring. The mobile middleware receives a request for a CMQ from context-aware application programs, receives sensor data from sensors, monitors whether the CMQ is satisfied, and transmits an event to the context-aware application programs according to results of the monitoring. In this case, the mobile middleware controls the sensors so that only sensor data required to determine whether the CMQ is satisfied needs to be transmitted so as to reduce energy consumption during the performance of the monitoring. Therefore, the mobile middleware can perform energy-efficient context monitoring, required by the context-aware application programs.